Author

J. Trowsdale

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Assay:flow cytometry· 1 Approach:statistical model· 1

Frequent Co-Authors

A. Campos Codo· 1 shared A. Getahun· 1 shared A. Ljungars· 1 shared A. Roghanian· 1 shared A. van Bokhoven· 1 shared B. Asquith· 1 shared B. Crute· 1 shared B. Frendeus· 1 shared

Activity by Year

2020-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 13 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

A. Campos Codo

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Inhibitory KIRs decrease HLA class II-mediated protection in Type 1 Diabetes

L. Mora-Bitria, B. J. Debebe, K. Miners, K. Ladell, C. Kaur, J. A. Traherne, W. Jiang, L. Hadcocks, N. A. R. McQuibban, J. Trowsdale, F. S. Wong, N. Pontikos, C. Niederalt, B. Asquith

The paper investigates how inhibitory KIRs modify HLA class II protective associations in Type 1 Diabetes, finding that iKIRs reduce HLA class II-mediated protection.

bioRxiv · Mar 27, 2024 · PreprintImmunology

Polymorphic KIR3DL3 expression modulates tissue-resident and innate-like T cells.

W. H. Palmer, L. A. Leaton, A. Campos Codo, P. S. Hume, B. Crute, M. Stone, A. van Bokhoven, R. P. Tobin, M. McCarter, W. J. Janssen, J. Roest, S. Zhu, J. Petersen, J. P. Vivian, J. Rossjohn, , P. J. Norman

This study identifies KIR3DL3 expression in T cells, showing it is upregulated by unconventional stimulation and varies by individual genetic variants.

bioRxiv · Aug 17, 2022Immunology

LILRB3 (ILT5) is a myeloid checkpoint on myeloid cells that elicits profound immununomodulation

M. Yeboah, C. Papagregoriou, D. C. Jones, H. T. C. Chan, G. Hu, J. S. McPartlan, T. Schiott, U. Mattson, C. I. Mockridge, U.-C. Tornberg, B. Hambe, A. Ljungars, M. Mattsson, I. Tews, M. J. Glennie, , A. Roghanian

This study identifies LILRB3 as a myeloid checkpoint receptor that suppresses immune responses through agonistic monoclonal antibodies, showing immunosuppressive effects in vitro and in humanized mice.

bioRxiv · Jun 4, 2020Immunology